Kay Hoong Chow

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia

David A. Rizzieri, Sarah Cooley, Olatoyosi Odenike et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 78 citations

Medicine, Oncology, Pharmacology +10

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua et al. · Clinical Pharmacology & Therapeutics · 2023 · 76 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Jhanelle E. Gray, Jeffrey R. Infante, Les Brail et al. · Investigational New Drugs · 2015 · 73 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Using fish gelatin and pectin to make a low-fat spread

Lai‐Hoong Cheng, Bock-Gu Lim, Kay Hoong Chow et al. · Food Hydrocolloids · 2007 · 65 citations

Agriculture, Food Science, Nutritional Sciences +5

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung et al. · Clinical Cancer Research · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17